Healthcare Equipment and Supplies
Company Overview of Cellnovo Limited
Cellnovo Limited, a medical technology company, develops and markets mobile diabetes management systems. The company’s mobile diabetes management system includes insulin patch pumps, and activity monitors, as well as cellular enabled wireless touchscreen handsets with integrated blood glucose meters and automatic connectivity to the cloud. Its touchscreen headset device is used for monitoring blood glucose, insulin, carbohydrate intake, and intensity and timing of daily activity, as well as for automatically recording insulin, blood glucose, food, and exercise related information. The company markets its insulin patch pump systems via a direct sales force in the United Kingdom and France, as...
Swansea, SA1 8AS
Key Executives for Cellnovo Limited
Cellnovo Limited does not have any Key Executives recorded.
Cellnovo Limited Key Developments
Cellnovo and Diabeloop Update on Artificial Pancreas
Jan 5 17
Cellnovo Group and Diabeloop announced that they have reached several milestones in their Artificial Pancreas programme. Cellnovo is currently participating in several major projects in both the US and Europe to develop an Artificial Pancreas system to enable the complete automation of insulin delivery. An Artificial Pancreas has the potential to provide more accurate regulation of blood-sugar levels in insulin-dependent people with Type 1 diabetes and to prevent hypoglycemic and hyperglycemic events and long-term complications that may arise from diabetes. The Artificial Pancreas system uses the information from the patient’s continuous blood glucose monitor (CGM) to calculate and deliver the optimal insulin dose to patients in real-time. The results of a first study of the Diabeloop algorithm, paired with the Cellnovo pump in 36 patients at 9 centres showed positive outcomes, which will be detailed by Diabeloop at the Advanced Technologies & Treatments for Diabetes conference (ATTD) taking place February 15-18 in Paris, France. Given the positive outcome, Cellnovo has delivered its first Bluetooth pumps to Diabeloop in preparation for the next clinical study, which will start in February 2017. This study will include 60 patients from 12 centres. The results are expected this year. This new study will be aimed at generating data for the purpose of obtaining a CE mark for the Diabeloop Artificial Pancreas combined with the Cellnovo System.
Cellnovo Limited Presents at 20th Oddo Midcap Forum, Jan-05-2017
Nov 21 16
Cellnovo Limited Presents at 20th Oddo Midcap Forum, Jan-05-2017 . Venue: Lyon’s Convention Center, 50 quai Charles de Gaulle, 69006 Lyon, France.
Cellnovo Group Files for 510(k) Approval with the FDA for its Mobile, Connected, All-in-One Diabetes Management System
Nov 16 16
Cellnovo Group has filed for 510(k) approval with the US Food and Drug Administration (FDA) for marketing clearance of the company's diabetes management system. The 510(k) is a premarket submission that must be filled with the FDA before a medical device can be launched and marketed in the US. Cellnovo can confirm that the submission is under review by the FDA, a process that the company expects to last several months. In anticipation of 510(k) approval, Cellnovo will continue preparations to ensure readiness for launch of the system in the US.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|